Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly nab-paclitaxel monotherapy versus docetaxel or gemcitabine as first-line treatment in elderly patients with advanced lung squamous carcinoma
ChiCTR1900023062Phase 4Recruiting
- Sponsor
- Union Hospital
- Start
- Apr 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of paclitaxel, docetaxel and gemcitabine in Pulmonary squamous cell carcinoma (2 arms), sponsored by Union Hospital. Primary endpoint: Progression-free survival. Started Apr 2019; status: recruiting.
02
Drugs
paclitaxeldocetaxelgemcitabine
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR1900023062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023062.